Stock SEQUENT SEQUENT SCIENTIFIC LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sequent Scientific Limited

Equities

SEQUENT

INE807F01027

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-05-03 am EDT 		5-day change 1st Jan Change
120.8 INR -1.31% Intraday chart for Sequent Scientific Limited -3.17% +6.15%
Apr. 04 Sequent Scientific's Joint Managing Director Resigns MT
Apr. 04 Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 18,753 17,634 18,981 58,952 33,033 18,037
Enterprise Value (EV) 1 21,293 20,177 21,812 61,119 36,092 22,056
P/E ratio 4.45 x 36.1 x 27.3 x 62.6 x 81.1 x -14.9 x
Yield 0.26% 0.28% - 0.21% - -
Capitalization / Revenue 2.21 x 1.7 x 1.61 x 4.33 x 2.34 x 1.27 x
EV / Revenue 2.51 x 1.94 x 1.85 x 4.49 x 2.55 x 1.55 x
EV / EBITDA 24.4 x 15.5 x 13.1 x 29.2 x 36.5 x 70.8 x
EV / FCF -58.8 x 49.3 x 63.3 x 80.4 x -859 x -39 x
FCF Yield -1.7% 2.03% 1.58% 1.24% -0.12% -2.56%
Price to Book 2.9 x 2.47 x 2.55 x 8.17 x 4.78 x 2.58 x
Nbr of stocks (in thousands) 242,291 245,426 244,289 244,717 246,880 248,471
Reference price 2 77.40 71.85 77.70 240.9 133.8 72.59
Announcement Date 8/9/18 8/5/19 8/3/20 8/30/21 8/29/22 8/8/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 8,478 10,393 11,792 13,616 14,128 14,209
EBITDA 1 871 1,299 1,661 2,092 987.6 311.6
EBIT 1 457.6 907.5 1,252 1,688 584.2 -153.5
Operating Margin 5.4% 8.73% 10.62% 12.39% 4.13% -1.08%
Earnings before Tax (EBT) 1 236.4 588.8 940.8 1,366 533.9 -1,377
Net income 1 4,216 486.6 699 954.4 412.5 -1,212
Net margin 49.72% 4.68% 5.93% 7.01% 2.92% -8.53%
EPS 2 17.40 1.990 2.850 3.850 1.650 -4.880
Free Cash Flow 1 -362.2 409.2 344.7 760.6 -42 -565.5
FCF margin -4.27% 3.94% 2.92% 5.59% -0.3% -3.98%
FCF Conversion (EBITDA) - 31.51% 20.76% 36.36% - -
FCF Conversion (Net income) - 84.09% 49.32% 79.69% - -
Dividend per Share 2 0.2000 0.2000 - 0.5000 - -
Announcement Date 8/9/18 8/5/19 8/3/20 8/30/21 8/29/22 8/8/23
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales 1 - 3,506 3,580 3,837
EBITDA 1 - 196.8 362.2 333.5
EBIT - - - -
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income 8.73 - 171.2 -
Net margin - - 4.78% -
EPS - - - -
Dividend per Share - - - -
Announcement Date 8/10/21 11/1/21 2/11/22 5/26/22
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 2,540 2,543 2,831 2,167 3,060 4,020
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.916 x 1.958 x 1.705 x 1.036 x 3.098 x 12.9 x
Free Cash Flow 1 -362 409 345 761 -42 -565
ROE (net income / shareholders' equity) 1.21% 7.95% 10.7% 13.9% 5.94% -16.4%
ROA (Net income/ Total Assets) 1.76% 4.15% 5.39% 7.39% 2.58% -0.64%
Assets 1 239,349 11,713 12,978 12,918 16,010 188,252
Book Value Per Share 2 26.70 29.10 30.50 29.50 28.00 28.10
Cash Flow per Share 2 1.630 2.790 2.800 2.180 2.320 1.670
Capex 1 470 254 407 528 325 862
Capex / Sales 5.55% 2.45% 3.45% 3.88% 2.3% 6.07%
Announcement Date 8/9/18 8/5/19 8/3/20 8/30/21 8/29/22 8/8/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SEQUENT SCIENTIFIC LIMITED Stock Sequent Scientific Limited
+6.15% 365M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SEQUENT Stock
  4. Financials Sequent Scientific Limited